NCT07248007

Brief Summary

Anal fistula is a common benign anorectal condition characterized by an abnormal tract between the anal canal and perianal skin, often resulting from cryptoglandular infection. Surgical fistulotomy remains the standard treatment for simple low anal fistulas, with success rates exceeding 90% . However,wound healing following fistulotomy can be prolonged,ranging from 6-10 weeks,which affects patient comfort, quality of life, and return to normal activity (1,2). After a fistulotomy, the tract is laid open, leaving behind a raw wound extending from the anal canal to the perianal skin.Traditionally,this wound is left open to heal by secondary intention(granulation and epithelialization). In marsupialization, the cut wound edges (the mucosa and anoderm/skin) are sutured to the wound base.Thismakesthewoundshallowerandkeepsitopenfordrainage.Itpreventsadeepcavitythat would otherwise take longer to granulate and epithelialize. Marsupialization of the wound edges has been introduced as a modification of standard fistulotomy to improve healing outcomes. Several randomized trials have shown that marsupialization accelerates wound healing (by 1-4 weeks) and preserves sphincter function better compared to leaving the wound open, without increasing recurrence or complications (3,4,5).

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P75+ for phase_1

Timeline
19mo left

Started Dec 2025

Typical duration for phase_1

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress22%
Dec 2025Nov 2027

First Submitted

Initial submission to the registry

November 18, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 25, 2025

Completed
6 days until next milestone

Study Start

First participant enrolled

December 1, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2027

Last Updated

November 25, 2025

Status Verified

October 1, 2025

Enrollment Period

1 year

First QC Date

November 18, 2025

Last Update Submit

November 18, 2025

Conditions

Keywords

anal fistula

Outcome Measures

Primary Outcomes (1)

  • Operative time

    messure the improvement of operative time between the PRP group and the non PRP group

    intra operative

Secondary Outcomes (1)

  • Post operative pain

    12 months

Study Arms (2)

PRP injection

ACTIVE COMPARATOR

a group of patients with simple anal fistula that will be treated with PRP following fistulotomy

Procedure: PRP injection

Non PRP group

NO INTERVENTION

the other group that will be treated with fistulotomy only without PRP

Interventions

PRP injectionPROCEDURE

Injection of PRP after fistulotomy in simple low anal fistula

PRP injection

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age18-65years. Both males and females. Clinical diagnosis of simple low anal fistula(confirmed by examination±imaging).
  • Simple fistula is defined as:
  • Fistula affecting less than one third of anal sphincter Fistula willnot affect sphincter function after surgery(no risk for fecal incontinence).
  • All types of low fistula which will not affect anal continence after surgery.

You may not qualify if:

  • Complex or high anal fistulas:
  • ( multiple tracts, suprasphincteric, extrasphincteric, or high transsphincteric tracts.) -Underlying diseases that impair healing: (Crohn's disease, ulcerative colitis, tuberculosis, HIV infection, anorectal malignancy)
  • Hematological disorders: coagulopathy, thrombocytopenia, or platelet dysfunction.
  • Systemic factors:
  • Uncontrolled diabetes mellitus. Immunosuppressive therapy (e.g., steroids, chemotherapy). Previous surgery for anal fistula (to avoid bias from scar tissue and recurrence)..
  • Known allergy to any agents used in PRP preparation (rare, e.g., calcium chloride).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Rectal Fistula

Condition Hierarchy (Ancestors)

Intestinal FistulaDigestive System FistulaDigestive System DiseasesIntestinal DiseasesGastrointestinal DiseasesRectal DiseasesFistulaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Central Study Contacts

Mohammed Osama, Resident

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: comparison between 2 groups of patients with simple anal fistula one group use PRP with fistulotomy in treatment and the other group only do fistulotomy
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Demonstrator

Study Record Dates

First Submitted

November 18, 2025

First Posted

November 25, 2025

Study Start

December 1, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

November 30, 2027

Last Updated

November 25, 2025

Record last verified: 2025-10